Lindbrook Capital’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Lindbrook Capital’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12	Closed	-$1.29K	–	2896
2023 Q1	$1.29K	Sell	12 -24	-67%	-$2.76K	﹤0.01%	2402
2022 Q4	$3.96K	Buy	36 +13	+57%	+$843	﹤0.01%	1938
2022 Q3	$1K	Buy	+23	New	+$1.05K	﹤0.01%	2575

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Lindbrook Capital's RXDX Position: Q2 2023 in Review

Lindbrook Capital sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 12 shares — an estimated $1.29K sold.

Lindbrook Capital first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $3.96K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Lindbrook Capital reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Lindbrook Capital sold 12 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.29K.
Lindbrook Capital first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Lindbrook Capital's Prometheus Biosciences, Inc. Common Stock position peaked at $3.96K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.